1000 related articles for article (PubMed ID: 34083418)
1. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
Zhao Z; Gao Y; Xue Q; Gao S; He J
Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
Nuccio A; Viscardi G; Salomone F; Servetto A; Venanzi FM; Riva ST; Oresti S; Ogliari FR; Viganò M; Bulotta A; Cameron R; Esposito A; Hines J; Bianco R; Reni M; Cascone T; Garassino MC; Torri V; Veronesi G; Cinquini M; Ferrara R
Eur J Cancer; 2023 Dec; 195():113404. PubMed ID: 37948842
[TBL] [Abstract][Full Text] [Related]
5. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
8. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
[TBL] [Abstract][Full Text] [Related]
10. [Application of Neoadjuvant Immuno-chemotherapy in NSCLC].
Chen S; Zhao Z; Long H
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):284-292. PubMed ID: 33910277
[TBL] [Abstract][Full Text] [Related]
11. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
Kang J; Zhang C; Zhong WZ
Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
[TBL] [Abstract][Full Text] [Related]
14. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
15. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
Christopoulos P
Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
[TBL] [Abstract][Full Text] [Related]
16. Current status of immune checkpoint inhibition in early-stage NSCLC.
Vansteenkiste J; Wauters E; Reymen B; Ackermann CJ; Peters S; De Ruysscher D
Ann Oncol; 2019 Aug; 30(8):1244-1253. PubMed ID: 31143921
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Advanced Lung Cancer.
Huang J; Reckamp KL
Oncology (Williston Park); 2020 Jul; 34(7):272-279. PubMed ID: 32674216
[TBL] [Abstract][Full Text] [Related]
18. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
19. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer].
Chen XY; Yang F
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]